AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,250,000 shares of common stock of the Company at a price to the public of $1.60 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions. (PRNewsfoto/AIkido Pharma Incorporated) H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The Company also has granted to the underwriter a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commission.   The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The offering is being conducted pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) on June 18, 2020. A final prospectus relating to the offering will be filed with the SEC and will be available on   Read more…